Nivolumab/Ipilimumab Combination Provides Longer Progression-Free Survival in Patients With Melanoma
By Walter Alexander
CHICAGO -- June 3, 2015 -- Adding nivolumab to ipilimumab results in longer progression-free survival and higher overall response rate than does ipilimumab alone in the treatment of patients with previously untreated melanoma, according to results of a phase 3 study presented at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).
These 2 agents represent distinct and complementary pathways that negatively regulate tumour immunity, explained lead investigator Jedd D. Wolchok, MD, Memorial Sloan Kettering Cancer Center, New York, New York, speaking at a press briefing here on May 31.
Dr. Wolchok and colleagues randomised 945 treatment-naïve patients (median age 61 years, about 65% male) with unresectable stage III or IV melanoma on a 1:1:1 basis to the following arms: Arm 1 -- nivolumab 1 mg/kg every 2 weeks + ipilimumab 3 mg/kg every 3 weeks for 4 doses followed by nivolumab 3 mg/kg every 2 weeks, Arm 2 -- nivolumab 3 mg/kg every 2 weeks + placebo, or Arm 3 -- ipilimumab 3 mg/kg every 3 weeks for 4 doses + placebo.
Patients continued until progression or unacceptable toxicity. PD-L1 expression was 5% or greater in about 24% of patients.
The coprimary endpoints were progression-free survival and overall survival (data not yet mature).
The researchers observed progression-free survival in the intent-to-treat population of 11.5 months for the combination, 6.9 months for nivolumab alone, and 2.9 months for ipilimumab alone. The hazard ratio for nivolumab/ipilimumab versus ipilimumab was 0.42 (P < .00001) and for nivolumab alone versus ipilimumab was 0.57 (P < .00001).
Overall response rates were 57.6% for the combination (P < .001 vs ipilimumab), 43.7% for nivolumab alone (P < .001 vs ipilimumab), and 19.0% for ipilimumab alone.
The median change in tumour burden, another secondary endpoint, was -51.9% for the combination, -34.5% for nivolumab alone, and +5.9% for ipilimumab.
Progression-free survival was longer and overall response rates higher in patients with PD-L1 expression of 5% or higher.
Grade 3 to 4 treatment-related adverse events were more common for patients in the combination arm (55.0% vs 16.3% for nivolumab alone and 27.3% for ipilimumab alone). Dr. Wolchok emphasised that 67.5% of patients who discontinued nivolumab/ipilimumab treatment for treatment-related adverse events still developed a response.
“Importantly for safety, we saw no drug-related deaths in the combination arm,” Dr. Wolchok stated.
[Presentation title: Efficacy and Safety Results from a Phase III Trial of Nivolumab (NIVO) Alone or Combined With Ipilimumab (IPI) Versus IPI Alone in Treatment-naive Patients (pts) With Advanced Melanoma (MEL) (CheckMate 067). Abstract LBA1]
DG News saves you time by delivering a short list of medical stories worthy of your time and attention. Our advanced algorithms rank clinical content based on hundreds of data points to surface the most important medical advances impacting your practice each week.